Literature DB >> 23162170

Scaleable processes for the synthesis of (-)-β-D-2,6-diaminopurine dioxolane (Amdoxovir, DAPD) and (-)-β-D-2-aminopurine dioxolane (APD).

Longhu Zhou1, Steven J Coats, Hongwang Zhang, Shi Junxing, Drew R Bobeck, Raymond F Schinazi.   

Abstract

An efficient and scalable synthesis of (-)-DAPD and (-)-APD has been developed. We discovered that t-butyl cyanoacetate can be used as a new additive for the sugar nucleoside base coupling step en route to DAPD with improved β-selectivity and an isolated yield four fold greater than the original process scale method. Using this new process, (-)-DAPD has been prepared on greater than 20 g scale. In the synthesis of (-)-APD, a key enzyme-catalyzed hydrolysis reaction afforded the water-soluble deprotected α-anomer while leaving the β-anomer completely untouched.

Entities:  

Year:  2012        PMID: 23162170      PMCID: PMC3496293          DOI: 10.1016/j.tet.2012.05.039

Source DB:  PubMed          Journal:  Tetrahedron        ISSN: 0040-4020            Impact factor:   2.457


  22 in total

Review 1.  Enantioselective enzymatic desymmetrizations in organic synthesis.

Authors:  Eduardo García-Urdiales; Ignacio Alfonso; Vicente Gotor
Journal:  Chem Rev       Date:  2005-01       Impact factor: 60.622

2.  Asymmetric synthesis of 1,3-dioxolane-pyrimidine nucleosides and their anti-HIV activity.

Authors:  H O Kim; S K Ahn; A J Alves; J W Beach; L S Jeong; B G Choi; P Van Roey; R F Schinazi; C K Chu
Journal:  J Med Chem       Date:  1992-05-29       Impact factor: 7.446

Review 3.  Recent advances in the use of enzyme-catalysed reactions in organic synthesis.

Authors:  N J Turner
Journal:  Nat Prod Rep       Date:  1989-12       Impact factor: 13.423

4.  Mechanism of action and in vitro activity of 1',3'-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants.

Authors:  Z Gu; M A Wainberg; N Nguyen-Ba; L L'Heureux; J M de Muys; T L Bowlin; R F Rando
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

5.  Pharmacokinetics of (-)-beta-D-2-aminopurine dioxolane and (-)-beta-D-2-amino-6-chloropurine dioxolane and their antiviral metabolite (-)-beta-D-dioxolane guanine in rhesus monkeys.

Authors:  H Chen; F D Boudinot; C K Chu; H M Mcclure; R F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

6.  Anti-HIV-1 activities of 1,3-dioxolane guanine and 2,6-diaminopurine dioxolane.

Authors:  Z Gu; M A Wainberg; P Nguyen-Ba; L L'Heureux; J M de Muys; R F Rando
Journal:  Nucleosides Nucleotides       Date:  1999 Apr-May

7.  Dioxolane guanosine, the active form of the prodrug diaminopurine dioxolane, is a potent inhibitor of drug-resistant HIV-1 isolates from patients for whom standard nucleoside therapy fails.

Authors:  Jennifer P Mewshaw; Florence T Myrick; Debby A C S Wakefield; Brandi J Hooper; Jeanette L Harris; Bruce McCreedy; Katyna Borroto-Esoda
Journal:  J Acquir Immune Defic Syndr       Date:  2002-01-01       Impact factor: 3.731

8.  In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3'-azido-3'-deoxythymidine.

Authors:  H Z Bazmi; J L Hammond; S C Cavalcanti; C K Chu; R F Schinazi; J W Mellors
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

9.  Enantioselective synthesis of bicyclo[3.1.0]hexane carbocyclic nucleosides via a lipase-catalyzed asymmetric acetylation. Characterization of an unusual acetal byproduct.

Authors:  Yuichi Yoshimura; Hyung R Moon; Yongseok Choi; Victor E Marquez
Journal:  J Org Chem       Date:  2002-08-23       Impact factor: 4.354

10.  Lack of pharmacokinetic interaction between amdoxovir and reduced- and standard-dose zidovudine in HIV-1-infected individuals.

Authors:  Selwyn J Hurwitz; Ghazia Asif; Emilie Fromentin; Phillip M Tharnish; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2009-12-28       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.